Wednesday, November 18, 2026

FDA Class II: Fresenius Medical Care Renal Therapies Group, LLC Recalls DELFLEX Peritoneal Dialysis Solution with 4.25% Dextrose, Low Magnesium/ Low Cal

Class II announced by FDA for DELFLEX Peritoneal Dialysis Solution with 4.25% Dextrose, Low Magnesium/ Low Calcium and Attached stay safe Exchange Set. Reason: Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag i...

NewsKrez Editorial DeskNovember 10, 2026 • 6:30 PM UTC
3 min read37 views
FDA Class II: Fresenius Medical Care Renal Therapies Group, LLC Recalls DELFLEX Peritoneal Dialysis Solution with 4.25% Dextrose, Low Magnesium/ Low Cal
Pharmaceutical product recall and laboratory testing.

The U.S. Food and Drug Administration (FDA) has posted an official drug enforcement report concerning Fresenius Medical Care Renal Therapies Group, LLC.

Product and Classification Details

  • Recall Number: D-0171-2027
  • Classification: Class II
  • Recalling Firm: Fresenius Medical Care Renal Therapies Group, LLC
  • Status: Ongoing

Reason for Enforcement Action

Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.

Distribution Information

Nationwide in the USA.

Official notification published per FDA Center for Drug Evaluation and Research (CDER) surveillance databases.
Regulatory Verification & Source Attribution

This intelligence report was compiled and verified by the NewsKrez Editorial & Regulatory Intelligence Desk in conjunction with openFDA Drug Enforcement & Recalls.

Sponsored Intelligence
Medical Device Software Compliance

Automated 21 CFR Part 820 & ISO 13485 Verification

Explore Solution →